From a target product profile to a franchise that compounds, Marga builds and runs the commercial strategy for aesthetics innovators, across neurotoxins, fillers, biostimulators, energy devices, and the skincare around them.
One team carrying a product from the science through to a durable franchise, instead of handing it between silos. The framework is standardized; every engagement is tailored to your product and your organization's needs.
End-to-end commercialization strategy, from the target product profile through positioning and pricing, so the commercial plan is shaped alongside the science rather than bolted on after it.
Turning the evidence into a claims and medical-education story the field will believe and repeat, built so the data and the message arrive as one.
A single coordinated launch plan across positioning, pricing, medical education, and field readiness, sequenced to land at the moment it matters most.
Real-world evidence, loyalty, portfolio, and franchise strategy that keep the product growing long past day one and defend it as the category crowds in.
Commissioned readouts resolve into the Marga Index™, a 360° score of your asset and your category, with the reasoning behind it. Other engagements draw on the same method.
Whether you are shaping a pipeline asset, preparing to launch, or defending a franchise, the work begins by connecting the decisions into one plan.